Volume 7.07 | Feb 25

Prostate Cell News 7.07 February 26, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
The MicroRNA-23b/-27b Cluster Suppresses Prostate Cancer Metastasis via Huntingtin-Interacting Protein 1-Related
Gene-expression profiling identified the endocytic adaptor, Huntingtin-interacting protein 1-related (HIP1R) as being downregulated by miR-23b/-27b. Increased HIP1R expression in prostate cancer cells inversely phenocopied the effects of miR-23b/-27b overexpression on migration, invasion and anchorage-independent growth. [Oncogene] Abstract
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

Secretory Leukocyte Protease Inhibitor Is a Survival and Proliferation Factor for Castration-Resistant Prostate Cancer
Scientists provide the first evidence that secretory leukocyte peptidase inhibitor (SLPI) is upregulated in a subset of castration-resistant prostate cancer (CRPC) cell lines and CRPC patient tumors. In addition, serum SLPI levels are significantly elevated in metastatic CRPC patients compared with hormone naive patients, raising the possibility that this could serve as a biomarker. [Oncogene] Abstract

P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer
Researchers observed that cancer stem cells (CSCs) isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Resistance was mediated by VEGF/neuropilin signaling, which was not inhibited by bevacizumab and sunitinib, and it involves the induction of P-Rex1, a Rac GEF, and consequent Rac1-mediated ERK activation [Cell Rep] Full Article | Graphical Abstract

The Essential Role of Methylthioadenosine Phosphorylase in Prostate Cancer
Investigators report the near universal retention of methylthioadenosine phosphorylase (MTAP) expression in a panel of human prostate cancer cell lines as well as patient samples. Upon metabolic perturbation, prostate cancer cell lines upregulated MTAP and this correlated with recovery of SAM levels. [Oncotarget] Full Article

Linneg Sca-1high CD49fhigh Prostate Cancer Cells Derived from the Hi-Myc Mouse Model Are Tumor-Initiating Cells with Basal-Epithelial Characteristics and Differentiation Potential In Vitro and In Vivo
The authors established a cell line from ventral prostate (VP) tumors of one-year-old Hi-Myc mice. These cells, called HMVP2 cells, were LinnegSca-1highCD49fhigh with high CD44 and CD29 expression and express CK14, Sca-1 and CD49f (but not CK8), suggesting basal-epithelial characteristics. [Oncotarget] Full Article

P38 MAPK Regulates the Wnt Inhibitor Dickkopf-1 in Osteotropic Prostate Cancer Cells
Inhibition of p38 MAPK signaling in osteolytic PC3 cells by small molecule inhibitors suppressed Dickkopf-1 (DKK-1) expression, whereas activation of p38 MAPK by anisomycin increased DKK-1. Further dissection by targeting individual p38 MAPK isoforms with siRNA revealed a stronger role for MAPK11 than MAPK14 and MAPK12 in the regulation of DKK-1. [Cell Death Dis] Full Article

Inhibition of AKT Promotes FOXO3a-Dependent Apoptosis in Prostate Cancer
Researchers demonstrated that inhibition of protein kinase-B (PKB)/AKT facilitates nuclear shuttling of Forkhead box O-3a (FOXO3a) where it regulates pro-apoptotic response-4 (Par-4) transcription in castration-resistant prostate cancer (CRPC) cells. FOXO3a is upstream of Par-4 signaling, which is required for induction of apoptosis in CRPC. [Cell Death Dis] Full Article

Targeting Fatty Acid Synthase with ASC-J9 Suppresses Proliferation and Invasion of Prostate Cancer Cells
Investigators found that androgen-deprivation-therapy with anti-androgens Bicalutamide or Enzalutamide had little effect to suppress fatty acid synthase expression and FASN-mediated cell growth and invasion during the castration resistant stage when the androgen concentration is 1 nM dihydrotestosterone. [Mol Carcinog] Abstract


Phytotherapeutic Interventions in the Management of Biochemically Recurrent Prostate Cancer: A Systematic Review of Randomized Trials
The authors evaluated the evidence from randomized trials for the efficacy and safety of phytotherapeutic interventions in the management of biochemically recurrent prostate cancer, indicated by prostate-specific antigen progression, numbers progressing to/time to initiation of androgen-deprivation therapy or salvage therapy. [BJU Int] Abstract

Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure: A Randomized, Double-Blind, Placebo-Controlled Phase III Bridging Study
Investigators evaluated the efficacy and safety of abiraterone acetate-prednisone versus placebo-prednisone in Asian metastatic castration-resistant prostate cancer patients who have failed docetaxel-based chemotherapy. [Int J Urol] Abstract

Learn More: Standardized Tools for Cancer Research
Current Use of PSMA-PET in Prostate Cancer Management
Prostate-specific membrane antigen (PSMA), a transmembrane protein that has considerable overexpression on most prostate cancer cells, has gained increasing interest as a target molecule for imaging. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
FDA Accepts for Review Supplemental New Drug Application for XTANDI® (Enzalutamide) Capsules in Metastatic Castration-Resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Astellas Pharma, Inc. and Medivation, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application that they have submitted for XTANDI® capsules in metastatic castration resistant prostate cancer, which includes findings from the Phase II TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. [Astellas Pharma, Inc.] Press Release

Senior Scientific and Weill Cornell Medicine to Pursue Non-Invasive Prostate Cancer Detection
Manhattan Scientifics, Inc. announced that its wholly-owned subsidiary Senior Scientific, LLC, has established a research collaboration with Weill Cornell Medicine. For the alliance, the company will bring its magnetic relaxometry technology to Weill Cornell Medicine, where scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate cancers. [Manhattan Scientifics, Inc.] Press Release

Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children
Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. [Cancer MoonShot 2020] Press Release

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW AACR Annual Meeting 2016
April 16-20, 2016
New Orleans, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellowship – Prostate and Breast Cancer Molecular Mechanisms (Feinberg School of Medicine)

NEW Tenure Track Faculty Positions – Various Methods in Cancer Biology (Paul L. Foster School of Medicine)

Postdoctoral Fellowship – Epidemiology of Prostate Cancer (Fred Hutchinson Cancer Research Center)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

PhD Position – Experimental Radiotherapy in Prostate Cancer (Katholieke Universiteit Leuven)

Postdoctoral Fellowship – Cancer Epigenomics (Princess Margaret Cancer Centre)

Postdoctoral Fellowship – Prostate Cancer Biology (Medical University of South Carolina )

Postdoctoral Fellowship – Prostate Cancer and Cancer Metabolism (Cleveland Clinic)

Post-Doc Fellowship – Metastasis of Cancer (University of Arizona Cancer Center)

Post-Doc Fellowship – Molecular Imaging for Prostate Cancer (Case Western Reserve University)

Post-Doc Fellowship/Staff Scientist – Prostate Cancer Epidemiology (Memorial Sloan Kettering Cancer Center)

Faculty Position – Urology Research (Mayo Clinic)

Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us